• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Oncolytics Biotech Inc. - Common Shares (NQ:ONCY)

0.9677 -0.0239 (-2.41%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 694,279
Open 0.9971
Bid (Size) 0.9500 (700)
Ask (Size) 0.9900 (2,500)
Prev. Close 0.9916
Today's Range 0.9600 - 1.010
52wk Range 0.3258 - 1.510
Shares Outstanding 46,166,980
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
The $170B Survival Race: Why Big Pharma is Snapping Up Late-Stage Cancer Tech
January 08, 2026
From Equity Insider
Via GlobeNewswire
News headline image
Oncolytics Biotech® Provides Update on Intellectual Property Strategy and Patent Filings
January 08, 2026
From Oncolytics Biotech Inc.
Via Business Wire

Performance

YTD
-1.6%
-1.6%
1 Month
-3.1%
-3.1%
3 Month
-17.3%
-17.3%
6 Month
-19.4%
-19.4%
1 Year
+11.3%
+11.3%

More News

Read More
News headline image
THE CHOKE POINT: 5 Assets That Control the Bottleneck
January 07, 2026
From Equity Insider
Via GlobeNewswire
News headline image
Oncolytics Biotech® Expands Its Gastrointestinal Tumor Scientific Advisory Board with the Addition of Dr. Eileen O’Reilly, Dr. Neil Segal, and Dr. Van Morris
January 07, 2026
From Oncolytics Biotech Inc.
Via Business Wire
News headline image
Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards
December 16, 2025
From Equity Insider
Via GlobeNewswire
News headline image
Oncolytics Biotech® Announces Promising Efficacy and Translational Data Supporting Pelareorep in KRAS-Mutant Metastatic Colorectal Cancer
December 16, 2025
From Oncolytics Biotech Inc.
Via Business Wire
News headline image
THE VISIBILITY INDEX: 5 Companies Solving the Invisible Crisis
December 15, 2025
From USA News Group
Via GlobeNewswire
News headline image
Oncolytics Biotech® Reschedules Special Meeting of Shareholders to Change Jurisdiction of Incorporation to Nevada
December 09, 2025
From Oncolytics Biotech Inc.
Via Business Wire
News headline image
GI Cancer Immunotherapy Breakthroughs Signal New Treatment Era
December 12, 2025
From Equity Insider
Via GlobeNewswire
News headline image
THE EFFICIENCY PARADOX: 5 Market Anomalies Trading Below Reality
December 06, 2025
From USA News Group
Via GlobeNewswire
News headline image
Curious about the stocks that are showing activity after the closing bell on Thursday? ↗
December 04, 2025
Via Chartmill
News headline image
UPDATE -- The Efficiency Gap: Five Assets Where Price Has Yet To Reflect Reality
December 03, 2025
From USA News Group
Via GlobeNewswire
News headline image
The Efficiency Gap: Five Assets Where Price Has Yet To Reflect Reality
December 03, 2025
From USA News Group
Via GlobeNewswire
News headline image
Oncolytics Biotech® Provides Update on Special Meeting of Shareholders
November 20, 2025
From Oncolytics Biotech Inc.
Via Business Wire
News headline image
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B
November 19, 2025
Via FinancialNewsMedia
News headline image
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B
November 19, 2025
From FN Media Group LLC
Via GlobeNewswire
News headline image
Oncolytics Biotech® Aligns with FDA on Pivotal Study Design for Pelareorep in First-Line Pancreatic Cancer
November 19, 2025
From Oncolytics Biotech Inc.
Via Business Wire
News headline image
Oncolytics Biotech® Establishes Gastrointestinal Tumor Scientific Advisory Board to Advance Pelareorep as a Platform Immunotherapy
November 04, 2025
From Oncolytics Biotech® Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
October 10, 2025
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
September 15, 2025
Via Benzinga
News headline image
Earnings Scheduled For August 8, 2025 ↗
August 08, 2025
Via Benzinga
News headline image
What to Expect from Oncolytics Biotech's Earnings ↗
August 07, 2025
Via Benzinga
News headline image
Global Oncology Breakthroughs Being Fueled by Advancements in Clinical Trials and New Therapies
July 08, 2025
Via FinancialNewsMedia
News headline image
Oncolytics Biotech® Highlights Transformative Pelareorep Survival Data in Multiple Tumors and Commitment to Registration-Enabling Studies
July 08, 2025
Via FinancialNewsMedia
News headline image
Global Oncology Breakthroughs Being Fueled by Advancements in Clinical Trials and New Therapies
July 08, 2025
From FN Media Group LLC
Via GlobeNewswire

Frequently Asked Questions

Is Oncolytics Biotech Inc. - Common Shares publicly traded?
Yes, Oncolytics Biotech Inc. - Common Shares is publicly traded.
What exchange does Oncolytics Biotech Inc. - Common Shares trade on?
Oncolytics Biotech Inc. - Common Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Oncolytics Biotech Inc. - Common Shares?
The ticker symbol for Oncolytics Biotech Inc. - Common Shares is ONCY on the Nasdaq Stock Market
What is the current price of Oncolytics Biotech Inc. - Common Shares?
The current price of Oncolytics Biotech Inc. - Common Shares is 0.9677
When was Oncolytics Biotech Inc. - Common Shares last traded?
The last trade of Oncolytics Biotech Inc. - Common Shares was at 01/09/26 04:00 PM ET
What is the market capitalization of Oncolytics Biotech Inc. - Common Shares?
The market capitalization of Oncolytics Biotech Inc. - Common Shares is 44.68M
How many shares of Oncolytics Biotech Inc. - Common Shares are outstanding?
Oncolytics Biotech Inc. - Common Shares has 45M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap